01 — At a Glance
A Pharmacy Distributor That Grows Like a D2C Startup (But Can’t Find Profit)
Market Cap: ₹4,717 crore | CMP: ₹1,084 | TTM Revenue: ₹6,020 crore | TTM PAT: ₹116 crore (1.9% margin) | YTD Return: +5.18% (3 months), -11.0% (1 year).
Entero is India’s third-largest pharmaceutical distributor (by revenue) and has delivered 152% earnings CAGR over five years. But here’s the plot twist: the stock is down 11% in the past year. The company is adding warehouses like Amazon on Diwali, acquiring competitors at breakneck speed, and growing revenue 26% year-over-year. Yet its operating cash flow? Negative ₹77 crore in FY25. Its ROCE is 8.7% — which is what you earn in a fixed deposit, except with 100 times more operational risk.
The Setup: Entero was incorporated in 2018, went public in Feb 2024 after raising ₹951 crore, and immediately started a acquisition spree like a teenager with a newly unlocked credit card. Q3 FY26 showed revenue of ₹1,707 crore (+26% YoY), but net profit of only ₹34 crore (adjusted ₹40 crore for a one-time labor code impact). The company is burning money to grow, and management is betting that one day — soon, they promise — it will all make sense. Spoiler: that day hasn’t arrived yet.
02 — Introduction
Welcome to the Pharmaceutical Distribution Thunderdome
Let’s talk about what Entero actually does, because if you ask 100 people on the street what a “pharmaceutical distributor” does, 99 will say “moves boxes,” and one will accidentally say “distribution network” and sound smart.
Here’s the reality: a pharmaceutical company makes insulin. A hospital needs insulin. The distributor is the middle-man who buys insulin in bulk, stores it in 113 warehouses across India, delivers it to 97,600+ retail pharmacies and 3,000+ hospitals, handles temperature control, manages returns, and skims a 8–10% margin (on turnover, not profit). If a pill expires, the distributor eats it. Literally. Not the pill — the loss. The margin model is what your SIP earns annually, except with the operational complexity of FedEx.
Entero was founded in 2018 by Prabhat Agarwal (ex-CEO of a pharma manufacturer — so he knows both sides) and Prem Sethi. The business model: acquire small regional distributors, consolidate them into a pan-India network, and export that scale to manufacturers who want a single point of contact instead of negotiating with 500 local distributors. It’s logical. It’s working. And it’s destroying cash flow in real-time.
By Feb 2024, Entero had IPO’d at ₹573/share, raised ₹951 crore, and immediately started buying other distributors. Since 2018, they’ve done 53 acquisitions. In Q3 FY26 alone: Anand Medilink, Ace Cardiopathy, Bioaide Technologies. Each acquisition brought inventory, working capital, and the promise of “synergies” — that magical accounting term for “we hope this makes sense in two years.”
The Concall Reality: In Feb 2026, the CEO conceded that FY26 guidance requires a “very strong Q4,” with operating cash flow expected to flip from -₹8 crore YTD to +₹100 crore full year. When an analyst asked if that meant “over ₹100 crores in Q4 alone,” the CEO replied: “Yes, that’s what we are shooting for.” Translation: “We are hoping for magic in the last quarter.” Hope is not a financial metric.
03 — Business Model: WTF Do They Even Do?
Moving Boxes Slowly. Growing Revenue Quickly. Losing Cash Always.
Entero operates a “two-way moat” (management’s term, not ours). More customers = more leverage with suppliers. Broader SKU access = more customers. A logical cycle. In practice? It’s a working-capital treadmill where inventory and receivables grow 2x faster than profit.
The Two Levers:
1. Demand Fulfillment: Buy pharma, devices, surgical goods, nutraceuticals from 3,100+ manufacturers. Store in 113 warehouses (spread across 47 cities, 500+ districts). Deliver to 97,600+ retail pharmacies, 3,000+ hospitals. Charge 8–10% margin. Pray that GST rates don’t change. (Spoiler: they do. In Q3, GST dropped from 12% to 5% on certain products, creating a one-time 17 bps tailwind.)
2. Demand Generation: Private labels (Entero Surgicals: nebulizers, gloves, PPE). Sales and marketing solutions. The higher-margin stuff. But it’s still tiny — management confessed private labels are “still pretty small.”
The New Bet: MedTech. Starting FY25, Entero is aggressively buying medical device distributors (Ace Cardiopathy, Bioaide, Anand Chemiceutics). Target: ₹1,000 crore annualized MedTech revenue by FY26-end. Why? MedTech has higher margins (because distributors “actively create demand,” not just fulfill it). Downside: MedTech also requires higher OpEx (more qualified staff, more marketing). So it’s higher margin on the GP line, but not necessarily on EBITDA.
Retail Pharmacy Customers97,600+Growing fast
Hospital Customers3,000+B2B stickiness
GLP-1s Hype Alert: Entero sells “almost 10% of GLP drugs” in India (CEO’s quote). Ozempic, Saxenda, whatever comes next. Sounds massive. Reality: GLP-1s are maybe 1–2% of total pharma market volume. If Entero captures 10% of a 1.5% market share, that’s ₹100–150 crore annualized. Good. Not transformative. Management used 15 minutes of concall time explaining why a single product category won’t transform the business. That itself should tell you something.
04 — Financials Overview
Q3 FY26: Revenue Grows, Profit Wheezes, Cash Drowns
Result type: Quarterly Results | Q3 FY26 EPS: ₹6.35 | Annualised EPS (Q3×4): ₹25.40 | Full-year FY25 EPS: ₹21.80
| Metric (₹ Million) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 170,700 | 135,900 | 157,100 | +25.6% | +8.7% |
| EBITDA | 6,800 | 5,000 | 6,200 | +36% | +9.7% |
| EBITDA Margin % | 4.0% | 3.7% | 3.9% | +30 bps | +10 bps |
| PAT (Reported) | 3,388 | 2,945 | 3,700 | +15% | -8.4% |
| EPS (₹) | 6.35 | 5.85 | 7.26 | +8.5% | -12.5% |
The Adjusted Story: Reported PAT looks weak (-8.4% QoQ), but management adjusted for a one-time labor code exceptional item of ₹61 million, which lifts PAT to ₹40 crore (+15% YoY). The adjusted profit margin was 2.3%. That’s a delivery business margin — the kind Amazon would kill for, and the kind a high-growth distributor should have transcended by now. Annualized EPS at ₹25.40, vs. LTM EPS of ₹25.91, suggests modest growth ahead. At a P/E of 40.5x, this stock is pricing in a narrative that hasn’t materialized: “Entero will be a 15%+ EBITDA-margin business.” The concalls say it might happen in FY27 or FY28. Investors are being asked to wait.
05 — Valuation: Show Me The Cash
What’s This Company Actually Worth (Without Believing the Magic)?
